Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect with cytogenetic remission and chronic graft-versus-host disease manifesting as polyserositis and subsequent bronchiolitis obliterans with organizing pneumonia

International Journal of Hematology

Volumn 76, Issue 4, 2002, Pages 360-364

  Law, L ^a   Tuscano, J ^a   Wun, T ^a   Ahlberg, K ^a   Richman, C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AML (M7); Bronchiolitis obliterans with organizing pneumonia; Filgrastim; Graft versus host disease; Graft versus leukemia; Peripheral stem cell transplant; Polyserositis; Relapse

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BRONCHIOLITIS OBLITERANS; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; DRUG MEGADOSE; EFFUSION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; ORGANIZING PNEUMONIA; TREATMENT OUTCOME; ACUTE NONLYMPHOCYTIC LEUKEMIA; ADOLESCENT; ALLOTRANSPLANTATION; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CHEMICALLY INDUCED DISORDER; CHROMOSOME ANALYSIS; CHRONIC DISEASE; FEMALE; GRAFT VERSUS HOST REACTION; METHODOLOGY; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION; REVIEW;

ADOLESCENT; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CHRONIC DISEASE; CYTOGENETIC ANALYSIS; FEMALE; FILGRASTIM; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HUMANS; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; SEROSITIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 1842863748     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982697     Document Type: Article

References (20)

1. Mortimer J, Blinder MA, Schulman S, et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol. 1989;7:50-57.
2. Bishop MR, Tarantolo SR, Pavletic ZS, et al. Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation. J Clin Oncol. 2000;18:2269-2272.
3. Giralt S, Escudier S, Kantarjian H, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med. 1993;329:757-761.
4. Curral A, Sanz GF, Sanz MA. Filgrastim for the treatment of leukemia relapse after bone marrow transplantation. Bone Marrow Transplant. 1996;18:817-819.
5. Noble PW. The pulmonary complications of bone marrow transplantation in adults. West J Med. 1989;150:443-449.
6. Einsele H, Ehninger G, Vallbracht A, et al. Isolated pericardial relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 1989;4:323-325.
7. Veys PA, McAvinchey R, Rothman MT, Mair GHM, Newlant AC. Pericardial effusion following conditioning for bone marrow transplantation in acute leukaemia. Bone Marrow Transplant. 1987;2:213-216.
8. Oeda E, Shinohara K, Kamel S, et al. Capillary leak syndrome likely the result of granulocyte colony-stimulating factor after high-dose chemotherapy. Intern Med. 1994;33:115-119.
9. de Azevedo AM, Tabak DG. Life-threatening capillary leak syndrome after G-CSF mobilization and collection of peripheral blood progenitor cells for allogeneic transplantation. Bone Marrow Transplant. 2001;28:311-312.
10. Toren A, Nagler A. Massive pericardial effusion complicating the course of chronic graft-versus-host disease (cGVHD) in a child with acute lymphoblastic leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;20:805-807.
11. Ueda T, Manabe A, Kikuchi A, et al. Massive pericardial and pleural effusion with anasarca following allogeneic bone marrow transplantation. Int J Hematol. 2000;71:394-397.
12. Seber A, Khan SP, Kersey JH. Unexplained effusion; association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease. Bone Marrow Transplant. 1996;17:207-211.
13. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood. 1994;84:3603-3612.
14. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
15. Pan L, Delmonte J Jr, Jalonen CK, et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward Type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422-4429.
16. Pan L, Takanori T, Geoffrey RH, et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood. 1999;93:4071-4077.
17. Collins RH, Rogers RR, Bennett M, et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant. 1992;10:391-395.
18. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant. 1998;22:873-881.
19. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175-181.
20. Isselbacher KJ, Martin JB, Fauci A, Baraunwald E, eds. Harrison's Principles of Internal Medicine. 13th edition. New York, NY: McGraw-Hill; 1994.